United States Department of Health and Human Services

Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine

ROCKVILLE, Md., Dec 27, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase I clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. The product candidate, a third generation vaccine being developed as part of Emergent’s anthrax franchise, consists of BioThrax(R) (Anthrax Vaccine Adsorbed) in combination with a novel immunostimulatory compound, CPG 7909.

Submitted by admin on Wed, 01/05/2011 - 05:30. categories [ ]

Emergent BioSolutions Hosts Biopreparedness Roundtable for NATO Parliamentarians

ROCKVILLE, Md., Jul 12, 2010 (BUSINESS WIRE) –

Submitted by admin on Tue, 07/13/2010 - 09:34. categories [ ]